Orthofix to acquire Spinal Kinetics in deal worth up to $105M

X-ray of cervical spine
Orthofix is acquiring Spinal Kinetics, which manufactures artificial cervical and lumbar discs, in a deal that could be worth up to $105 million.

Devicemaker Orthofix is acquiring Spinal Kinetics, which manufactures artificial cervical and lumbar discs, in a deal that could be worth up to $105 million.

Under terms of the agreement, $45 million in cash will be paid upfront with an additional $60 million at stake given certain milestones are reached, including FDA approval of the M6-C cervical disc and if trailing 12-month sales targets of $30 million and $50 million are hit, the company said.

Spinal Kinetics’ M6-C cervical and M6-L lumbar artificial discs are designed for patients suffering from degenerative disc disease of the spine. These devices mimic the structure of a natural disc by using an artificial visco-elastic nucleus and fiber annulus that provides 6 degrees of motion, similar to a natural disc.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“This technology is a significant advancement in mimicking the natural motion of the spine, which we believe will be very beneficial to patients and well received by our surgeon customers,” Brad Mason, Orthofix’s president and CEO, said in a statement. “This acquisition is very well aligned with our value creation strategy of accelerating topline growth by investing in faster growing market segments in our core businesses.”

The M6 artificial discs have already received a CE Mark and Spinal Kinetics has submitted a PMA to the FDA for the M6-C cervical disc to be used in treating single level cervical degenerative disc disease. More than 54,000 implants of the M6-C and M6-L have been done globally since the devices were launched in 2006.

Suggested Articles

The FDA has cleared its first duodenoscope designed to make the intricate, moving and difficult-to-clean parts in the head of the device disposable.

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.